Why more pharma manufacturers are turning to inline CCIT to prevent costly losses
Summary
Pharmaceutical manufacturers continue to face one recurring challenge: container closure issues that are only detected after production is complete. The result? Costly product losses, compliance risks, and wasted resources.
This case study explains why more companies are moving away from destructive sampling and adopting 100% in-line, non-destructive Container Closure Integrity Testing (CCIT). You’ll see how Gasporox solutions like VialArch™ and BottleArch™ help prevent million-euro losses by detecting deviations in real time, without slowing production.
Technology
The Gasporox sensors and instruments are built on more than 25 years of development and refinement in industrial laser-based gas measurement. The system uses Tunable Diode Laser Absorption Spectroscopy (TDLAS), a highly reliable and precise method for non-destructive headspace gas analysis.
Developed by Gasporox in collaboration with its technology partners, this laser sensor technology is widely used in demanding industries such as pharmaceuticals, petrochemicals, and energy.
Gasporox’s laser-based headspace analysis has been successfully deployed for over a decade in pharmaceutical manufacturing. It is integrated into fully automated inspection systems and benchtop instruments for 100% in-line and laboratory testing of vials, ampoules, and other parenteral packaging formats. The performance and robustness of the system have been validated through extensive real-world use.